[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-386263-105":59,"doc-detail-386263-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ribonucleotide-reductase-regulatory-subunit-m2-rrm2-as-a-potential-sero-diagnostic-biomarker-in-non-small-cell-lung-cancer","Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer","","Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with most patients diagnosed at advanced stages using existing tumor markers. The study analyzes four Gene Expression Omnibus datasets to assess RRM2 mRNA in paired NSCLC tissues and measures serum RRM2 via ELISA alongside CYFRA21-1, ProGRP, CEA, and NSE. RRM2 is elevated in tumors and in patient serum, correlating with distant metastasis and histological type. ROC analysis indicates improved diagnostic performance for NSCLC using RRM2 alone compared with traditional markers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ribonucleotide-reductase-regulatory-subunit-m2-rrm2-as-a-potential-sero-diagnostic-biomarker-in-non-small-cell-lung-cancer/386263/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ribonucleotide-reductase-regulatory-subunit-m2-rrm2-as-a-potential-sero-diagnostic-biomarker-in-non-small-cell-lung-cancer/386263.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To identify RRM2 as a potential sero-diagnostic biomarker for non-small cell lung cancer (NSCLC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were RRM2 and traditional tumor markers measured?",{"text":117,"@type":113},"RRM2 mRNA was assessed in paired tissues using reverse transcription quantitative PCR, while serum RRM2 was measured by ELISA. Serum levels of CYFRA21-1, ProGRP, CEA, and NSE were measured using electrochemiluminescence immunoassays.",{"name":119,"@type":110,"acceptedAnswer":120},"Which clinical factors were associated with serum RRM2 levels?",{"text":121,"@type":113},"Serum RRM2 levels were associated with distant metastasis and histological type, but not with tumor size or lymph node metastasis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},386263,1790620511,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","PLOS ONE  \nOPEN ACCESS  \nCitation: Zhou D, Zhai X, Zhang R (2023)  \nRibonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer. PLoS ONE 18(9): e0291461 . [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0291461  \nEditor: Ziheng Wang, University of Macau, MACAO  \nReceived: April 27, 2023  \nAccepted: August 22, 2023  \nPublished: September 12, 2023  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here:  \n[https://doi.org/10.1371/journal.pone.0291461](https://doi.org/10.1371/journal.pone.0291461)  \n[Copyright:](Copyright:) © [2023 Zhou](2023 Zhou) et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the paper and its Supporting Information files.  \nFunding: This work was financially supported by the Xinglin Scholar Research Premotion Project of  \nRESEARCH ARTICLE  \nRibonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer  \nDandan Zhou1,2, Xiuming Zhai1 *, Ruixue Zhang3  \n1 Department of Clinical Laboratory, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China, 2 Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing, 400021, China, 3 School of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China  \n* [xiumingzhai@163.com](xiumingzhai@163.com)  \nAbstract  \nObjectives  \nNon-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Most cases are diagnosed at an advanced stage using current tumor markers. Here, we aimed to identify potential novel potential biomarkers for NSCLC.  \nMaterial/Methods  \nFour independent datasets from the Gene Expression Omnibus database were analyzed. The relative expression of ribonucleotide reductase regulatory subunit M2 (RRM2) mRNA in 30 paired of NSCLC paired tissues was measured by reverse transcription quantitative PCR. Serum levels of cytokeratin fragment 21–1 (CYFRA21-1), pro-gastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), and neuron-specific enolase (NSE) were measured using electrochemiluminescence immunoassays, and serum RRM2 levels were evaluated by an enzyme-linked immunosorbent assay.  \nResults  \nThe mRNA expression level of RRM2 was significantly increased in most NSCLC lesions compared to para-adjacent tissues. Serum RRM2 levels in NSCLC patients were significantly elevated compared to healthy controls and were also associated with distant metastasis and histological type, but not with tumor size or lymph node metastasis. Receiver operating characteristic curve analysis showed a higher diagnostic ratio for NSCLC using RRM2 alone compared to other traditional tumor markers.  \nConclusions  \nRRM2 is a potential sero-diagnostic biomarker for NSCLC.  \nPLOS ONE | [https://doi.org/10.1371/journal.pone.0291461](https://doi.org/10.1371/journal.pone.0291461) September 12, 2023 1 / 17  \nChengdu University of TCM (Grant No.: YYZX2020069) . The grant recipient is Zhou, D. D., and the funder provided assistance in study design, data collection, and manuscript analysis.  \nCompeting interests: The authors have declared that no competing interests exist.  \nIntroduction  \nLung cancer has become a leading cause of malignant tumor-related deaths worldwide, and in China, it has the highest mortality rate of cancer cases [ 1]. Lung cancer is broadly classified into small cel","cbCaivBoHMGrSa3V","https://ap.wps.com/l/cbCaivBoHMGrSa3V","pdf",2362661,17,"English","# Abstract\n## Objectives\n## Material/Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To identify RRM2 as a potential sero-diagnostic biomarker for non-small cell lung cancer (NSCLC).\"},{\"question\":\"How were RRM2 and traditional tumor markers measured?\",\"answer\":\"RRM2 mRNA was assessed in paired tissues using reverse transcription quantitative PCR, while serum RRM2 was measured by ELISA. Serum levels of CYFRA21-1, ProGRP, CEA, and NSE were measured using electrochemiluminescence immunoassays.\"},{\"question\":\"Which clinical factors were associated with serum RRM2 levels?\",\"answer\":\"Serum RRM2 levels were associated with distant metastasis and histological type, but not with tumor size or lymph node metastasis.\"}]","Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer | PDF",1790273019,43]